Search clinical trials for: Tiotropium bromide low

Total 8566 results

Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Tiotropium in Cystic Fibrosis Patients

Cystic Fibrosis
Boehringer Ingelheim

Completed

Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Canada, Germany, Netherlands, Sweden
Boehringer Ingelheim

Completed

Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis

Cystic Fibrosis

United States, Australia, Belgium, France, Germany, Italy, Netherlands, New Zealand, Portugal, Russian Federation, United Kingdom
Boehringer Ingelheim
Pfizer

Completed

Randomised, Double- Blind, Cross-over Efficacy and Safety Comparison of Three Different Doses of Tiotropium Administered Once Daily Versus Placebo in Patients With Moderate Persistent Asthma.

Asthma

Austria, Germany, Ukraine
Boehringer Ingelheim
Pfizer

Completed

Efficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma

Asthma

United States, Germany, Latvia, Lithuania, Slovenia
McMaster University
Boehringer Ingelheim

Completed

Study to Evaluate the Effects of Tiotropium Bromide on Chronic Obstructive Pulmonary Disease (COPD) During Exercise

COPD
Duke University

Withdrawn

Tiotropium Handihaler vs. Tiotropium Respimat in COPD

Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca

Completed

Clinical Trial to Assess Rate of Onset of Bronchodilator Action in Severe Stable Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease (COPD)

United Kingdom
Xiromed LLC
Laboratorios Liconsa; Exeltis

Completed

Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD) (ARBORUS)

COPD

United States, India
Boehringer Ingelheim

Completed

Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)

Pulmonary Disease, Chronic Obstructive

United States, Canada, Germany
Guangzhou Institute of Respiratory Disease
Boehringer Ingelheim

Recruiting

Effect of Tiotropium Bromide Combined With Odaterol on Small Airway Remodeling in Patients With Mild to Moderate Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

China
Boehringer Ingelheim

Completed

Observational Study of Adherence to LABA / LAMA in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany
Boehringer Ingelheim

Completed

RUSSE / Russian Spiriva® Safety & Efficacy Study

COPD

Russian Federation
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Study Comparing Tiotropium Easyhaler and Spiriva Handihaler

Healthy Subjects

Finland
Boehringer Ingelheim

Completed

Effect of Tiotropium Inhalation Capsules (Spiriva) on Exercise Tolerance in COPD Patients

Pulmonary Disease, Chronic Obstructive

Italy
Boehringer Ingelheim

Completed

Effects of Once Daily Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) of Different Severity

Pulmonary Disease, Chronic Obstructive

Germany
Boehringer Ingelheim

Completed

Effect of Tiotropium (Spiriva) on Exercise Tolerance in COPD Patients

Pulmonary Disease, Chronic Obstructive

Canada, Germany, United States, Australia
Boehringer Ingelheim

Completed

Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2

Pulmonary Disease, Chronic Obstructive

United States
Boehringer Ingelheim

Completed

Mechanisms of Dyspnea Relief During Exercise in COPD Patients Following Treatment With Tiotropium (Spiriva)

Pulmonary Disease, Chronic Obstructive

Canada
AstraZeneca

Completed

Efficacy and Safety of Aclidinium Bromide 400 µg Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Czech Republic, Germany, Hungary, Poland
Boehringer Ingelheim
Pfizer

Completed

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma

Asthma

United States, Belgium, Finland, Germany, Korea, Republic of, Latvia, Lithuania, Malaysia, Netherlands, Philippines, Ukraine
Boehringer Ingelheim
Pfizer

Completed

A Study to Evaluate Efficacy and Safety of Tiotropium in Children 6 to 11 Years Old With Moderate Asthma

Asthma

Germany, Hungary, Latvia, Lithuania, Russian Federation, Ukraine
Boehringer Ingelheim

Completed

Efficacy of Tiotropium in Patients of African Descent With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United States
Boehringer Ingelheim

Completed

Tiotropium Respimat Pharmacokinetic Study in COPD

Pulmonary Disease, Chronic Obstructive

Belgium, Denmark, Finland, Germany, Netherlands
Boehringer Ingelheim

Completed

Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD) in Daily Practice

Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline

Completed

Effect of GSK1160724 In Healthy Volunteers

Pulmonary Disease, Chronic Obstructive

United Kingdom
Boehringer Ingelheim

Completed

Tiotropium in the Treatment of the Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Japan
Boehringer Ingelheim

Completed

Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Effect of Spiriva® 18 Microgram on Health-related Quality of Life and Physical Functioning in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Proven Hyperinflation

Pulmonary Disease, Chronic Obstructive
Novartis

Completed

Safety, Tolerability and Pharmacodynamics of QAX028 Compared to Open-label Tiotropium Bromide and Placebo in Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD) Patients.

COPD

Denmark
Boehringer Ingelheim

Completed

Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1

Pulmonary Disease, Chronic Obstructive

United States, Puerto Rico
University of Saskatchewan

Completed

Tiotropium Efficacy Against Allergen Induced Early Asthmatic Responses

Allergic Asthma

Canada
Novartis Pharmaceuticals

Completed

Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD Patients (FAVOR)

Chronic Obstructive Pulmonary Disease | COPD

Germany
Boehringer Ingelheim

Completed

Spiriva (Tiotropium Bromide) Assessment of FEV1 - (SAFE-Portugal).

Pulmonary Disease, Chronic Obstructive

Portugal
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Study Comparing Tiotropium Easyhaler® and Spiriva® HandiHaler® (TESSA)

Healthy Volunteers

Finland
Boehringer Ingelheim

Completed

A Study Based on Medical Records That Looks at the Duration of Use of Two Types of Inhalers With Different Medicines in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States
Nephron Pharmaceuticals Corporation
Rho, Inc.

Completed

Tiotropium Bromide Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD)

United States
Huashan Hospital

Unknown

Efficiency of Budesonide Combined With Formoterol and Tiotropium in the Treatment of Acute Exacerbation of ACO

Asthma-COPD Overlap
Boehringer Ingelheim

Completed

Study to Investigate Safety and Tolerability of BI 1744 CL in Free Dose Combination With Tiotropium Bromide Both Administered by Respimat® in Healthy Male Volunteers

Healthy
University Hospital, Ghent
Boehringer Ingelheim

Completed

Study to Investigate the Effect of Inhaled Tiotropium Bromide on Neurokinin-A Induced Bronchoconstriction in Patients With Mild-to-moderate Asthma

Asthma

Belgium
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

A Trial to Assess the Bioequivalence of Generic Tiotropium Bromide Inhalation Powder and Reference Product in Healthy Adult Participants Under Fasting Conditions (Pilot)

Chronic Obstructive Pulmonary Disease

China
Boehringer Ingelheim

Completed

Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to LABA/ICS

COPD

United States
Novartis

Completed

1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD) (GLOW2)

Chronic Obstructive Pulmonary Disease

United States, Argentina, Germany, Russian Federation, France, Israel, Korea, Republic of, Italy, Poland, Chile, Mexico, Peru, Canada, Hungary, Netherlands, New Zealand
Boehringer Ingelheim
Pfizer

Completed

Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.

Pulmonary Disease, Chronic Obstructive

Austria, Belgium, Bulgaria, Czech Republic, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Latvia, Lithuania, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slovakia, Slovenia, Spain, Turkey, Ukraine, United...
Boehringer Ingelheim

Completed

Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients After Switching to Tiotropium Plus Olodaterol Fixed Dose Combination in Greece

Pulmonary Disease, Chronic Obstructive

Greece
Henan University of Traditional Chinese Medicine
ShuGuang Hospital

Unknown

Bufei Yishen Granule for Reducing Acute Exacerbation in GOLD Stage 3 or 4 COPD

Chronic Obstructive Pulmonary Disease

China
Boehringer Ingelheim

Completed

A Comparison of 18g of Tiotropium Inhalation Capsules Once Daily and Atrovent Metered Dose Inhaler (2 Puffs of 20g, 4 Times Daily) in a Double-Blind, Double-Dummy, Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

China
Orion Corporation, Orion Pharma

Completed

Comparison of Tiotropium Absorption From Tiotropium Easyhaler and Spiriva HandiHaler (TEMPO)

Healthy Volunteers

Finland
Boehringer Ingelheim

Terminated

Assessment of Health-related Quality of Life After Switching COPD Patients From a Dry Powder Inhaler to a Soft Mist Inhaler Remaining on the Same Inhalative Drug (NIS PIRATE)

Pulmonary Disease, Chronic Obstructive

Switzerland
Boehringer Ingelheim

Completed

Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study

Pulmonary Disease, Chronic Obstructive

United States

3

Subscribe